Damora Therapeutics (DMRA) Total Current Liabilities (2019 - 2026)
Damora Therapeutics (DMRA) posted Total Current Liabilities of $23.8 million for Q1 2026, up 18.67% on a QoQ basis from $20.1 million in Q4 2025, and up 1388.25% year-over-year from $1.6 million in Q1 2025.
Damora Therapeutics (DMRA) Total Current Liabilities (2019 - 2026) Analysis & Trends
Damora Therapeutics' Total Current Liabilities history runs 8 years deep, the most recent figure standing at $23.8 million for Q1 2026.
- Quarterly Total Current Liabilities rose 1388.25% year-over-year to $23.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.8 million (up 1388.25% YoY) and the FY2025 annual result came in at $20.1 million, up 1572.17% from the prior year.
- Total Current Liabilities was $23.8 million for Q1 2026 at Damora Therapeutics, up from $20.1 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $23.8 million in Q1 2026 and bottomed at $1.2 million in Q4 2024.
- A 5-year average of $8.5 million and a median of $7.2 million in 2022 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Current Liabilities tumbled 80.95% — and 2025, when it jumped 1572.17%.
- Damora Therapeutics' Total Current Liabilities stood at $11.1 million in 2022, then sank by 47.48% to $5.8 million in 2023, then sank by 79.42% to $1.2 million in 2024, then soared by 1572.17% to $20.1 million in 2025, then gained by 18.67% to $23.8 million in 2026.
- Business Quant data shows DMRA's Total Current Liabilities at $23.8 million in Q1 2026, $20.1 million in Q4 2025, and $2.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Damora Therapeutics | 1.00 Bn | 798.11 Mn | - | 23.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.81 Mn |
| Dec 31, 2025 | 20.07 Mn |
| Sep 30, 2025 | 2.62 Mn |
| Jun 30, 2025 | 2.63 Mn |
| Mar 31, 2025 | 1.60 Mn |
| Dec 31, 2024 | 1.20 Mn |
| Sep 30, 2024 | 2.40 Mn |
| Jun 30, 2024 | 3.71 Mn |
| Mar 31, 2024 | 4.32 Mn |
| Dec 31, 2023 | 5.83 Mn |
| Sep 30, 2023 | 12.60 Mn |
| Jun 30, 2023 | 14.90 Mn |
| Mar 31, 2023 | 14.06 Mn |
| Dec 31, 2022 | 11.10 Mn |
| Sep 30, 2022 | 8.90 Mn |
| Jun 30, 2022 | 7.50 Mn |
| Mar 31, 2022 | 7.20 Mn |
| Dec 31, 2021 | 4.54 Mn |
| Sep 30, 2021 | 5.74 Mn |
| Jun 30, 2021 | 4.80 Mn |